Breaking News

Batavia Biosciences Advances Polio Vaccine Production

Leverages the HIP-Vax platform using a novel fixed-bed bioreactor technology.

Author Image

By: Charlie Sternberg

Associate Editor

An overview of the scale-X fixed-bed bioreactor and NevoLine sIPV prototype.

Batavia Biosciences, a contract development and manufacturing organization (CDMO), has pioneered a novel upstream bioprocessing method to enhance regional polio vaccine production. This advancement leverages the HIP-Vax platform using a novel fixed-bed bioreactor technology to streamline vaccine manufacturing while reducing biosafety risks and lowering production footprint. Polio vaccine production presents unique challenges. Current manufacturing methods often struggle with scalability and c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters